Pancreas Journal
Overview
Publication venue for
- A Pilot Phase 2 Study of Albumin-Bound Rapamycin Nanoparticles, ABI-009, in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors (NETs) of the Lung or Gastroenteropancreatic System. 48:449-449. 2019
- Capecitabine/Temozolomide Chemotherapy in Metastatic Neuroendocrine Tumors: Response Rate and Survival by Grade. 48:453-453. 2019
- Clinical Utility of a Molecular Cancer Classifier for Primary Site Identification in Neuroendocrine Tumors. 48:454-454. 2019
- Current Practices and Novel Techniques in the Diagnosis and Management of Neuroendocrine Tumors of Unknown Primary. 48:1111-1118. 2019
- Lanreotide vs. Octreotide-LAR for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Observational Time and Motion Analysis. 48:450-450. 2019
- Molecular Characteristics of Small-Bowel Neuroendocrine Tumors. 48:435-435. 2019
- Plasma Pancreastatin Levels Predict the Outcome of Surgical Cytoreduction in Neuroendocrine Tumors of the Small Bowel. 48:456-456. 2019
- Plasma Pancreastatin Predicts the Outcome of Surgical Cytoreduction in Neuroendocrine Tumors of the Small Bowel. 48:356-362. 2019
- Role of Plasma Pancreastatin in Predicting Prognosis Following R0/R1 Surgical Cytoreduction in Small Bowel Neuroendocrine Tumors. 48:456-456. 2019
- Does Plasma Neurokinin A Predict Survival in Well-Differentiated Neuroendocrine Tumors (NETs) of the Small Bowel?. 47:359-359. 2018
- Plasma Neurokinin A Levels Predict Survival in Well-Differentiated Neuroendocrine Tumors of the Small Bowel. 47:843-848. 2018
- Predictive Rates of Survival Based on Ki-67 and Chemotherapy Regimens in Patients with High Grade (HG) Neuroendocrine Tumors (NETs). 47:339-340. 2018
- Correlation of Angiogenic Markers in Neuroendocrine Tumors and Their Prognostic Implications. 46:427-427. 2017
- Liver Needle Biopsies Are Poor Predictors of Histologic Tumor Grade for Midgut Neuroendocrine Tumors. 46:443-443. 2017
- Incidence of Nodal Positivity in Appendiceal Neuroendocrine Tumors (NETs) and Its Effect on Survival. 45:486-486. 2016
- The Role of Capecitabine/Temozolomide (CAPTEM) in Metastatic Neuroendocrine Tumors: A Neuroendocrine Tumor Program Experience. 45:480-480. 2016
- Theranostics With I-131/I-123 Meta-Iodobenzylguanidine (MIBG) in Stage IV Advanced Malignant Neuroendocrine Tumors. 44:351-351. 2015
- Preliminary Experience with Intra-Arterial I-131 MIBG Hepatic Infusion for Progressive Metastatic Low Grade Neuroendocrine Tumors: An Ongoing Work-in-Progress. 42:371-371. 2013
- Surgical Treatment Options for Rectal Carcinoid Cancer: Trans-Anal Excision versus Low Anterior Resection with Total Mesorectal Excision. 42:385-385. 2013
- Cervical and Upper Mediastinal Lymph Node Metastasis from GI and Pancreatic Neuroendocrine Tumors: Incidence and Management. 41:350-350. 2012
- Hepatic Artery Radioembolization (HARE) in the Management of Progressive Metastatic Neuroendocrine Tumors (NETs): A Survival and Biochemical Response Analysis in Geriatric (G) and Young (Y) Populations. 41:345-346. 2012
- Neurokinin A Levels Predict Survival in Patients with Well Differentiated Small Bowel Neuroendocrine Tumors. 41:345-345. 2012
- Treatment of Small Bowel Neuroendocrine Tumors (NETS) in a Multidisciplinary Specialty Center Increases Survival. 41:351-351. 2012
- Short Term Response to Systemic I-131 MIBG Therapy in Metastatic Carcinoid Tumors. 40:325-325. 2011
Identity
International Standard Serial Number (ISSN)
- 0885-3177